Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).

D OrsiniM MegnaC AssorgiA BalatoR BalestriN BernardiniA BettacchiTommaso BianchelliL BianchiG BuggianiMartina BurlandoAmg BrunassoG CaldarolaN CameliA CampanatiE CampioneA CarugnoK ChersiA ContiA CostanzoE CozzaniA CucciaD D'AmicoG Dal BelloE G Dall'OlioP DapavoC De SimoneE V Di BrizziA Di CesareV DiniM EspositoE ErrichettiM C FargnoliC S FiorellaA FotiZ FrattonF M GaianiP GisondiR GiuffridaA GiuntaC GuarneriA LegoriF LoconsoleP MalagoliA NarcisiM PaolinelliLuca PotestioF PrignanoG RechA RossiN SkrozaF TrovatoM VenturiniA G RichettaG PellacaniA Dattola

Published in: The Journal of dermatological treatment (2024)

Conclusions: Bimekizumab is a suitable option for elder patients as it is effective, tolerated and has a convenient schedule.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
clinical trial
single cell
cross sectional